Continuous glucose monitoring (CGM) following islet transplantation (ITx) has shown improved time-in-range, reduced glycemic variability (GV) and hypoglycemia prevention despite subnormal beta-cell function. However, it is unclear if improvement by CGM persists long-term in insulin independent (Ifree) ITx recipients. We evaluated 5 ITx recipients who remained Ifree for >5 years. Subjects completed 7-day non-blinded CGM (Dexcom G4 Platinum). HbA1c, 90min C-peptide, Clarke score, and BETA-2 score (composite measure of beta-cell function after ITx) were obtained. Before ITx, mean age was 47.2±4.0 years, diabetes duration 34.6±9.4 years, HbA1c 7.0±1.2%, insulin/Kg/day 0.44±0.08 units and Clarke score 5 (range 4-7). Subjects received 1-2 islet infusions. Induction immunosuppression consisted of ATG or daclizumab and dual maintenance with sirolimus, tacrolimus or mycophenolate mofetil. At time of CGM, subjects were Ifree and 10.7±3.5 years post-ITx (range 7.7-16.0). Two subjects were on non-insulin adjunct therapies. CGM and metabolic data, BETA-2 and Clarke scores are shown in Table 1. In Ifree ITx recipients with very good long-term graft function (BETA-2 score>15) and restoration of hypoglycemia awareness, CGM shows near-normalization of time-in-range and GV with minimal time-in-hypoglycemia. ITx is a successful long-term cellular therapy for T1D in a selected group of patients.

D. Baidal: None. A.M. Alvarez Gil: None. N. Padilla: None. C. Ricordi: Advisory Panel; Self; Zone Labs. R. Alejandro: None.


National Institute of Allergy and Infectious Diseases/National Institute of Diabetes and Digestive and Kidney Diseases (U01-DK-070460); Immune Tolerance Network (NIS01); Diabetes Research Institute Foundation; State of Florida; University of Miami Clinical and Translational Science Institute (1UL1TR000460); JDRF International (4-2004-361)

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at